{"related:1Cqqnpx7U0sJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673607619047","authors":["B Escudier","B Escudier A Pluzanska","B Escudier A Pluzanska P Koralewski","B Escudier A Pluzanska P Koralewski A Ravaud…"],"year":2007,"numCitations":2570,"pdf":"https://journals.viamedica.pl/nowotwory_journal_of_oncology/article/download/52342/39075","citationUrl":"http://scholar.google.com/scholar?cites=5427817888518646484&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:1Cqqnpx7U0sJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5427817888518646484&hl=en&as_sdt=0,5","publication":"Elsevier","p":1,"exp":1596898399539},{"title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2007,"numCitations":6133,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","citationUrl":"http://scholar.google.com/scholar?cites=12674526305022444340&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:NAM1m4X25K8J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12674526305022444340&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651074/","authors":["BI Rini","BI Rini S Halabi","BI Rini S Halabi JE Rosenberg…"],"year":2008,"numCitations":1022,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651074/","citationUrl":"http://scholar.google.com/scholar?cites=18273808260162582187&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:q_aWOMubmf0J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=18273808260162582187&hl=en&as_sdt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa066838","authors":["G Hudes","G Hudes M Carducci","G Hudes M Carducci P Tomczak…"],"year":2007,"numCitations":4021,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa066838","citationUrl":"http://scholar.google.com/scholar?cites=11854457709475007825&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:UQ0mqnp-g6QJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11854457709475007825&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","url":"http://s-space.snu.ac.kr/handle/10371/77398","authors":["CN Sternberg","CN Sternberg ID Davis","CN Sternberg ID Davis J Mardiak…"],"year":2010,"numCitations":2448,"pdf":"http://s-space.snu.ac.kr/bitstream/10371/77398/1/Sternberg-2010-Pazopanib%20in%20Locally.pdf","citationUrl":"http://scholar.google.com/scholar?cites=17868513553253356300&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:DFPrvWe2-fcJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=17868513553253356300&hl=en&as_sdt=0,5","publication":"s-space.snu.ac.kr"},{"title":"Sorafenib in advanced clear-cell renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa060655","authors":["B Escudier","B Escudier T Eisen","B Escudier T Eisen WM Stadler…"],"year":2007,"numCitations":5345,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa060655","citationUrl":"http://scholar.google.com/scholar?cites=4193023401754303534&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Lhx3fJGcMDoJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4193023401754303534&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673608610399","authors":["RJ Motzer","RJ Motzer B Escudier","RJ Motzer B Escudier S Oudard","RJ Motzer B Escudier S Oudard TE Hutson","RJ Motzer B Escudier S Oudard TE Hutson C Porta…"],"year":2008,"numCitations":3182,"pdf":"http://www.academia.edu/download/53999404/s0140-6736_2808_2961039-920170728-7660-zx8w1m.pdf","citationUrl":"http://scholar.google.com/scholar?cites=8449425975912964334&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:7iBAeihkQnUJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8449425975912964334&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673611616139","authors":["BI Rini","BI Rini B Escudier","BI Rini B Escudier P Tomczak","BI Rini B Escudier P Tomczak A Kaprin","BI Rini B Escudier P Tomczak A Kaprin C Szczylik…"],"year":2011,"numCitations":1695,"citationUrl":"http://scholar.google.com/scholar?cites=3547505814206124423&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:h5FjFr5FOzEJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3547505814206124423&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3646307/","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2009,"numCitations":2287,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3646307/","citationUrl":"http://scholar.google.com/scholar?cites=9930987091739607833&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:GQMhsCT00YkJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9930987091739607833&hl=en&as_sdt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB …","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2860433/","authors":["BI Rini","BI Rini S Halabi","BI Rini S Halabi JE Rosenberg…"],"year":2010,"numCitations":862,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2860433/","citationUrl":"http://scholar.google.com/scholar?cites=3956532382067211975&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:xz5yJz1t6DYJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3956532382067211975&hl=en&as_sdt=0,5","publication":"ncbi.nlm.nih.gov"}]}